These findings underscore the importance of targeting the FOSL1‐IL‐6‐STAT3Tyr705‐stemness axis as a means to combat chemoresistance and GBM stemness, thereby providing a promising therapeutic strategy to improve outcomes for patients with GBM. This evidence concerns the gene IL6 and glioblastoma.